Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +76.67% and +17.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Prelude Therapeutics (PRLD) delivered earnings and revenue surprises of +14.29% and +12.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical (DERM) delivered earnings and revenue surprises of -66.67% and -7.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0.00% and -6.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -5.88% and -11.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Gainers
Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million.
SCWorx (NASDAQ:WORX) shares movedread more...
Gainers
Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million.
Vivos Therapeutics (NASDAQ:VVOS) stockread more...
Vivos Therapeutics (NASDAQ:VVOS) held its second-quarter earnings conference call on Friday. Below is the complete transcript from the call.
This content is powered by Benzinga APIs. For comprehensive financial data andread more...
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +26.19% and -5.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?